That compensation is determined according to the language of the Uruguay Round Agreements Act, the GATT implementing legislation. On that point, let me reference the letter from the Department of Health and Human Services about the Thurmond-Hatch substitute. This is the agency which would have to implement the substitute. The letter states that ``it will be nearly impossible to meet the `substantial investment' requirement'' under the substitute. Elsewhere, it concludes the substitute ``defines substantial investment--a matter that the URAA left to the courts--and does so in a manner that would make it virtually impossible for a generic drug company to meet the requirement.''
William Pryor: “That compensation is determined according to the language of the Uruguay Round Agreements Act, the GATT implementing…”
Editor's note · Context
Discussing the implications of the Thurmond-Hatch substitute on generic drug companies.
Share
More from William Pryor
I want to thank our House colleagues for working hard down the hall here in getting a bipartisan bill. We have a bipartisan bill. But I think there are three fundamental differences between their bill and our bill. One, our bill has more…
I rise in honor of today's Take Our Daughters and Sons to Work Day when, over the past 15 years, individuals, families and workplaces have joined in expanding opportunities and transforming the lives of millions of girls and boys both…
I want to pause for 1 minute and thank all of the cosponsors on this legislation. There was a committee bill and the bill that passed the floor a few moments ago. I thank everybody who helped work on this, even those who voted against it…
I was encouraged yesterday by the vote we had at 5:30. Here, again, we find that the Consumer Product Safety Commission is an agency that needs our reform. They need us to come in and to not just give them more resources--it is not a…